Identification of a Frameshift Mutation in Osterix in a Patient with Recessive Osteogenesis Imperfecta  by Lapunzina, Pablo et al.
REPORT
Identification of a Frameshift Mutation in Osterix
in a Patient with Recessive Osteogenesis Imperfecta
Pablo Lapunzina,1,2,7 Mona Aglan,3,7 Samia Temtamy,3,7 Jose´ A. Caparro´s-Martı´n,1,4 Maria Valencia,1,4
Rocı´o Leto´n,1,4,8 Victor Martı´nez-Glez,1,2 Rasha Elhossini,3 Khalda Amr,3 Nuria Vilaboa,5,6
and Victor L. Ruiz-Perez1,4,*
Osteogenesis imperfecta, or ‘‘brittle bone disease,’’ is a type I collagen-related condition associated with osteoporosis and increased risk of
bone fractures. Using a combination of homozygosity mapping and candidate gene approach, we have identiﬁed a homozygous single
base pair deletion (c.1052delA) in SP7/Osterix (OSX) in an Egyptian child with recessive osteogenesis imperfecta. The clinical ﬁndings
from this patient include recurrent fractures, mild bone deformities, delayed tooth eruption, normal hearing, and white sclera. OSX
encodes a transcription factor containing three Cys2-His2 zinc-ﬁnger DNA-binding domains at its C terminus, which, in mice, has
been shown to be essential for bone formation. The frameshift caused by the c.1052delA deletion removes the last 81 amino acids of
the protein, including the third zinc-ﬁnger motif. This ﬁnding adds another locus to the spectrum of genes associated with osteogenesis
imperfecta and reveals that SP7/OSX also plays a key role in human bone development.Osteogenesis imperfecta (OI, MIM 166200, MIM 166210,
MIM 259420, MIM 166220) is a bone-related genetic
disorder characterized by low bone mass and bone fragility
that is clinically and genetically heterogeneous. Patients
with OI have clinical features that may range from mild
symptoms with a scant number of fractures to severe
bone deformities and neonatal lethality.1 Most cases of
OI are caused bymutations in the type I procollagen genes,
COL1A1 (MIM 120150) and COL1A2 (MIM 120160), and
follow an autosomal-dominant pattern of inheritance.2
Type I collagen is a structural component of the connective
tissue that is initially synthesized as a procollagen
precursor in the endoplasmic reticulum (ER) by the combi-
nation of two procollagen a1 (I) and one procollagen a2 (I)
peptide chains paired together into a triple helix, a process
that is assisted by a number of molecular chaperons and ER
enzymes. Type I procollagen trimers are then exported into
the extracellular matrix and transformed into functionally
competent type I collagen molecules by the proteolytic
removal of the N-terminal and C-terminal propeptides.3
In a minority of cases with severe or lethal autosomal-
recessive OI, there have been mutations identiﬁed in the
three components of the ER collagen 3-hydroxylation
complex, comprising prolyl 3-hydroxylase 1 (LEPRE1,
MIM 610339), cartilage-associated protein (CRTAP, MIM
605497), and peptidylprolyl isomerase B (PPIB, MIM
123841).4–7 These three proteins are responsible for the
3-hydroxylation of a speciﬁc residue, Pro986, in the
collagen a1 (I) chains.8 Although the function of this
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Recently, also in a family with severe OI and recessive
inheritance, a homozygous missense mutation
(c.233T>C, p.Leu78Pro) was found in SERPINH1 (MIM
600943; Serpin peptidase inhibitor, clade H), the gene en-
coding the ER chaperone-like protein HSP47 (heat shock
protein 47).10 SERPINH1 was ﬁrst linked to OI by homozy-
gosity mapping in a canine pedigree of Dachshunds.11
Biochemical analysis of patient-derived primary ﬁbroblasts
demonstrated that the p.Leu78Pro HSP47 mutant variants
were subjected to proteasome-mediated degradation,
whereas there was accumulation of type I procollagen in
the Golgi and abnormal folding of a proportion of the
secreted type I collagen. Because Pro986 3-hydroxylation
was found to be normal in the HSP47 mutant cells, it
was concluded that this protein is required downstream
of the CRTAP/LEPRE1/PPIB protein complex.10 Finally,
two mutations have been reported in FKBP10 (MIM
607063) in patients with moderately severe OI and reces-
sive disease transmission.12 FKBP10 codes for FKBP65,
which is a protein with known type I procollagen chap-
erone function. Investigation of the FKBP65 mutations in
dermal ﬁbroblasts from affected individuals revealed
normal 3-hydroxylation of the proline 986 but delayed
secretion of type I procollagen.12 Hence, so far all the genes
associated with OI are involved in the synthesis, posttrans-
lational modiﬁcation, trafﬁcking, processing, or secretion
of type I collagen. Herein we report the genetic analysis
of a family that has led us to the identiﬁcation of an addi-
tional gene mutated in this disease.de Gene´tica Me´dica y Molecular, Hospital Universitario La Paz-IdiPaz,
Genome Research Division, National Research Centre, 12311 Cairo, Egypt;
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Figure 1. Clinical Findings in the Patient with
an OSX Mutation
(A) Photographs of the reported patient showing
bowing of the long bones of the arms (top) and sabre
tibia (bottom).
(B–E) Radiographical ﬁndings in the proband at the
age of 8 years.
(B) X-ray of the right upper limb (lateral view)
demonstrating anterior bowing, deformed irregular
humerus, radius, and ulna, and generalized
decreased bone density. An old, improperly healed
fracture at the lower third of the humerus and trans-
verse fractures of the radius and ulna are indicated by
small arrows. The long arrow designates a transverse
line of arrested bone growth at the lower end of the
radius.
(C) X-ray of the right leg (lateral view) showing
decreased bone density with anterior bowing of the
tibia and ﬁbula and transverse fracture at the lower
third of the tibia (arrow).
(D) X-ray of the pelvis and upper ends of femora
(anterior-posterior view) demonstrating a deformed
asymmetric pelvis with thin laterally displaced
neck of the femur, bilaterally, mostly on the right
side. There is an old, improperly healed fracture at
the upper end of right femur with callus formation
(arrow).
(E) X-ray of the skull (lateral view) showing wormian
bones at the occipital region (arrow).We have studied the case of an Egyptian 8-year-old boy
with OI born to consanguineous parents related as second
cousins (Figure 1; Figure 2A). The family had a history of
a similarly affected sibling who, in addition to OI with
repeated bone fractures, was diagnosed with a congenital
heart condition and died at the age of 4 years as a result
of pneumonia. We did not see the deceased child, and
thus no DNA from this individual was available for molec-
ular studies. Fractures in the proband started at 3 months
of age, and since then they occurred frequently, mostly
following minor trauma, with an average of 6–7 fractures
per year. The number of fractures decreased after the
patient began biphosphonate treatment (see Table S1 avail-
able online). The child has had delayed motor milestones:
he sat at the age of 1 year, was not able to stand unsup-
ported until the age of 6 years, and he is not able to walk
independently at the age of 8 years. His hearing and sclerae
were normal. Craniofacial features included a skull with
wormian bones, mild asymmetry of the face, high promi-
nent forehead with prominent supraorbital ridges more
obvious on the right side, midface hypoplasia, depressed
nasal bridge, microstomia, micrognathia, and high arched
palate. Delayed teeth eruption was noted, but he did not
have dentinogenesis imperfecta. Radiographic examina-
tion of the skeletal system revealed bowing of the upper
and lower limbs; his right leg was shorter than his left leg
because of bone deformities, and he also presented hyper-The Aextensibility of the interphalangeal joints, mild scoliosis,
and mild pectus carinatum (Figure 1). Anthropometric
measurements for length were below normal (3.6 stan-
dard deviation [SD] at the age of 8 years), and head circum-
ference and weight were within normal range for his age
(þ0.9 SD and 2.1 SD, respectively, at the age of 8 years).
Bone densitometry performed by dual energy X-ray ab-
sorptiometry (DEXA) revealed generalized osteoporosis
(Z score of 3.4 at the lumbar spine and 1.9 at the femur
at the age of 4 years, before the start of biphosphonate
treatment). Anthropometric and DEXA data related to
the follow-up of this patient are listed in Table S1. Based
on the phenotype, a diagnosis of OI type IVwas considered
following the Sillence classiﬁcation guidelines.1 All studies
and investigations involving the proband and other
members of his family were performed in accordance
with the ethical standards of the Medical Research Ethics
Committee of the National Research Centre (Egypt), and
all DNA samples were obtained with appropriate informed
consent.
Recurrence in a sibling and parental consanguinity sug-
gested a recessive pattern of inheritance, and on this basis
we embarked on the genetic analysis of this family. Micro-
satellite analysis in the proband, his father, and two of the
unaffected siblings excluded linkage to COL1A1, COL1A2,
LEPRE1, and CRTAP under a recessive disease model,
because the patient was heterozygous for markersmerican Journal of Human Genetics 87, 110–114, July 9, 2010 111
Figure 2. Identification of a Frameshift
Mutation in Osterix
(A) Pedigree of the OI family analyzed in
this study; the proband (P) is designated
with an arrow.
(B) Alignment of genomic sequence chro-
matograms corresponding to an area en-
compassing the c.1052delA mutation
from a normal individual (N), a heterozy-
gous carrier (C), and the proband (P). The
adenine deleted in the patient is squared
in gray. Numbering of the mutation corre-
lates to the reference sequence
NM_152860.1, taking the A of the transla-
tion start site as nucleotide þ 1.
(C) Protein effect of the c.1052delA muta-
tion. The picture on the top shows the
position of the three zinc ﬁngers repre-
sented by blue rectangles in the normal
(Wt) and mutant (Mut) SP7 proteins. The
mutant protein is missing the third zinc
ﬁnger, and the new residues incorporated
after the frameshift are indicated in red.
The lower panel shows the sequence of
amino acids corresponding to the DNA
binding region of normal and mutant
OSX. Conserved cysteine and histidine
residues involved in zinc ion coordination
corresponding to each individual zinc
ﬁnger are highlighted in different colors.
The amino acids inserted after the muta-
tion are in red. Protein numbering is
related to the reference sequence
NP_690599.1.surrounding these loci. We also sequenced the ﬁve coding
exons of PPIB, the ﬁve exons of SERPINH1, and all of the
coding exons of COL1A1 and COL1A2, including the in-
tronic boundaries, but no pathogenic sequence variations
were found in the patient DNA. To search for the causative
gene, we performed homozygosity mapping in the
proband and one of his unaffected sisters by using
genome-wide high-density SNP arrays (Illumina
Human610-Quad BeadChip). The two SNP genotypes
generated by this process were then analyzed with Illu-
mina software to look for blocks of homozygosity. Taking
an arbitrary cutoff of 300 consecutive homozygous SNPs,
we found ﬁve large regions of homozygosity in the patient
that were not shared by his normal sibling. These regions
were located on chromosome 2 (two DNA segments of
3.5 and 3.1 Mb), chromosome 4 (8.1 Mb), chromosome
11 (14.5 Mb), and chromosome 12 (19.3 Mb) and
contained 29, 22, 92, 410, and 332 genes, respectively
(Genome Reference Consortium Human Build 37.1). Eval-
uation of the transcripts comprised in each region revealed
the presence of a candidate gene, SP7/OSX (MIM 606633),
in the homozygosity block of chromosome 12 (12q13.13).
We considered OSX to be a good candidate for the disease
because it encodes an osteoblast-speciﬁc transcription
factor that, in mice, has been shown to be indispensable
for bone formation. Osx null mice are deﬁcient in
osteoblast differentiation and have reduced expression of112 The American Journal of Human Genetics 87, 110–114, July 9, 20osteoblast markers, including Col1a1, Bone sialoprotein,
and Osteocalcin.13 In addition, these mice display bone-
bending deformities similar to those seen in patients
with OI.13 We screened the proband for the presence of
OSX mutations by genomic ampliﬁcation followed by
direct sequencing of the two SP7 coding exons and at least
100 bp of the adjacent intronic sequences, and we identi-
ﬁed a homozygous single nucleotide deletion,
c.1052delA, in the last exon of this gene (Figure 2B). The
frameshift caused by this mutation introduces 18 novel
residues at codon 351 before running into a premature
termination codon (p.E351GfsX19). Segregation analysis
of the mutation within the family showed that the two
parents were heterozygous for the nucleotide deletion
and that out of the ﬁve normal siblings from whom we
could obtain DNA, three carried the mutation in the
heterozygous state and two had normal sequence. We
checked normal controls for the presence of the
c.1052delA change by direct sequencing, but it was not
found in 122 control chromosomes of the same ethnic
origin or in 284 normal chromosomes from controls of
mixed ethnicity.
Because the c.1052delAmutation introduces a premature
stop codon within the ﬁnal exon of the gene, the mutant
transcript is predicted to escape the nonsense-mediated
mRNA decay machinery.14 OSX is a 431 amino acid
protein that belongs to the Speciﬁcity protein (Sp)10
subgroup of the Kru¨ppel-like family of transcription factors
characterized by the invariable presence of three tandem
Cys2-His2 zinc-ﬁnger DNA-binding domains at their car-
boxy terminus.15–17 Based on crystallography and nuclear
magnetic resonance studies performed in some members
of the family, it has been established that each protein
ﬁnger recognizes a consecutive trinucleotide sequence,
with the three zinc ﬁngers contributing to the strength
and speciﬁcity of the DNA-protein interaction.18–20 Sp1,
which is the best-characterized member of the Sp group
and is closely related to SP7, binds GC-rich DNA boxes of
9 base pairs. Previous experimental studies, including
DNA-binding assays, that used Sp1 peptide fragments in
which either the N-terminal (1) or the C-terminal (3)
zinc ﬁngers were deleted demonstrated a greater contribu-
tion of ﬁnger 3 to the DNA-binding afﬁnity than the other
two remaining ﬁngers.21,22 The p.E351GfsX19 change
leads to a truncated SP7 protein that lacks the last 81
amino acids, including the third Zn-ﬁnger domain, and
carries instead 18 new residues downstream of codon 351
(Figure 2C). Thus, in the case in which the OSX mutant
variant is not degraded by the proteasome, its DNA-
binding properties are expected to be altered, and, conse-
quently, the SP7/OSX-mediated transcription regulation
will be impaired. Mutations in the third Zn ﬁnger of
EGR2 (MIM 129010), a very similar Cys2-His2 transcrip-
tion factor, have been described in patients with auto-
somal-recessive congenital hypomyelinating neuropathy
(MIM 605253), proving that mutations in the third zinc
ﬁnger can lead to disease.23 A limitation of this work is
that in vivo studies to assess the effect of theOSXmutation
on transcript and protein stability and on type 1 collagen
production in patient cells could not be performed because
of the unavailability of additional biological material from
the patient.
Sp7/Osx is speciﬁcally expressed in cortical and trabec-
ular osteoblasts and at a lower level in the prehypertrophic
chondrocytes of the growth plate.13 This restricted expres-
sion pattern is consistent with the patient having normal
white sclera. Analysis of Osx mouse models has revealed
that Osx plays an essential role in regulating the differenti-
ation of preosteoblasts to osteoblasts in a step downstream
of Runx2 (MIM 600211),13 another transcription factor
that is a master regulator for osteoblast differentiation
and that, in humans, is responsible for cleidocranial
dysplasia (MIM 119600).24 Although Runx2 null mice do
not express Osx, Runx2 expression was shown to be unaf-
fected in the developing bones of Osx/ mutants.13 In
agreement with the craniofacial features identiﬁed in our
patient, both endochondral and intramembranous bone
formations were found to be disrupted in the Osx null
mice. Because constitutive ablation of Osx is perinatal
lethal, the function of Osx in adult bone has been studied
by using conditional models. Postnatal inactivation of Osx
with tamoxifen inducible Col1a1-CreERT2mice resulted in
impaired bone formation as a result of reduced expression
of osteoblast-speciﬁc markers.25 OSX function has notThe Abeen explored in detail in humans, but the DNA region
around OSX has been identiﬁed as one of the osteoporosis
susceptibility loci. Several genome-wide association studies
have shown signiﬁcant association of common variants in
the region of OSX with bone mineral density (BMD) and
osteoporosis, although this association could not be as-
signed unequivocally to this gene.26–28 To assess whether
the c.1052delA OSX mutation could have an effect on
adult BMD in the heterozygous state, we performed
DEXA scans in the parents of our patient. The 39-year-
old mother had normal bone density at the femur (T score
0.4) and osteopenia at the spine (T score 1.3). The 61-
year-old father had borderline osteoporosis of the spine
and osteoporosis of the femur (T scores 2.2 and 3.0,
respectively). However, the father has been on corticoste-
roid therapy for the treatment of lung ﬁbrosis since the
age of 43 years and had already been identiﬁed as having
progressive osteoporosis and bilateral glaucoma 2 years
after the beginning of this treatment. He also has a history
of partial thyroidectomy at the age of 39 years, and he is on
L-thyroxine, but thyroid functions are not regulated.
Because it is known that prolonged corticosteroid therapy
can induce osteoporosis, we cannot conclude from these
data that the low BMD of the father is a direct consequence
of being a heterozygous carrier for the OSX mutation.
In summary, the data we present here add onemore gene
to the growing number of causative loci for autosomal-
recessive OI and indicate that mutations in transcription
factors that regulate the expression of osteoblast-speciﬁc
genes can also be accountable for OI. Further testing is
required to ascertain what proportion of autosomal-reces-
sive OI cases arise from mutations in OSX.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.ajhg.org.Acknowledgments
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